131 related articles for article (PubMed ID: 11939309)
21. Apoptotic and proliferative index after Alpha-1-adrenoceptor antagonist and/or finasteride treatment in benign prostatic hyperplasia.
Erdoğru T; Ciftcioglu MA; Emreoglu I; Usta MF; Koksal T; Ozbilim G; Gulkesen KH; Baykara M
Urol Int; 2002; 69(4):287-92. PubMed ID: 12444285
[TBL] [Abstract][Full Text] [Related]
22. Finasteride in the treatment of benign prostatic hyperplasia.
Ekman P; Andersen JT; Wolf H
Acta Urol Belg; 1996 Mar; 64(1):IX-XII. PubMed ID: 8659328
[TBL] [Abstract][Full Text] [Related]
23. Prostatic disorders in the dog.
Johnston SD; Kamolpatana K; Root-Kustritz MV; Johnston GR
Anim Reprod Sci; 2000 Jul; 60-61():405-15. PubMed ID: 10844211
[TBL] [Abstract][Full Text] [Related]
24. Long-term effects of finasteride in patients with benign prostatic hyperplasia: a double-blind, placebo-controlled, multicenter study. PROWESS Study Group.
Marberger MJ
Urology; 1998 May; 51(5):677-86. PubMed ID: 9610579
[TBL] [Abstract][Full Text] [Related]
25. Effect of finasteride treatment on suburethral prostatic microvessel density in patients with hematuria related to benign prostate hyperplasia.
Memis A; Ozden C; Ozdal OL; Guzel O; Han O; Seckin S
Urol Int; 2008; 80(2):177-80. PubMed ID: 18362489
[TBL] [Abstract][Full Text] [Related]
26. Can finasteride reverse the progress of benign prostatic hyperplasia? A two-year placebo-controlled study. The Scandinavian BPH Study Group.
Andersen JT; Ekman P; Wolf H; Beisland HO; Johansson JE; Kontturi M; Lehtonen T; Tveter K
Urology; 1995 Nov; 46(5):631-7. PubMed ID: 7495111
[TBL] [Abstract][Full Text] [Related]
27. Evidence for atrophy and apoptosis in the prostates of men given finasteride.
Rittmaster RS; Norman RW; Thomas LN; Rowden G
J Clin Endocrinol Metab; 1996 Feb; 81(2):814-9. PubMed ID: 8636309
[TBL] [Abstract][Full Text] [Related]
28. Combined sabal and urtica extract compared with finasteride in men with benign prostatic hyperplasia: analysis of prostate volume and therapeutic outcome.
Sökeland J
BJU Int; 2000 Sep; 86(4):439-42. PubMed ID: 10971268
[TBL] [Abstract][Full Text] [Related]
29. Efficacy and safety of finasteride therapy for benign prostatic hyperplasia: results of a 2-year randomized controlled trial (the PROSPECT study). PROscar Safety Plus Efficacy Canadian Two year Study.
Nickel JC; Fradet Y; Boake RC; Pommerville PJ; Perreault JP; Afridi SK; Elhilali MM
CMAJ; 1996 Nov; 155(9):1251-9. PubMed ID: 8911291
[TBL] [Abstract][Full Text] [Related]
30. Comparison of dutasteride and finasteride for treating benign prostatic hyperplasia: the Enlarged Prostate International Comparator Study (EPICS).
Nickel JC; Gilling P; Tammela TL; Morrill B; Wilson TH; Rittmaster RS
BJU Int; 2011 Aug; 108(3):388-94. PubMed ID: 21631695
[TBL] [Abstract][Full Text] [Related]
31. Sustained decrease in incidence of acute urinary retention and surgery with finasteride for 6 years in men with benign prostatic hyperplasia.
Roehrborn CG; Bruskewitz R; Nickel JC; McConnell JD; Saltzman B; Gittelman MC; Malek GH; Gottesman JE; Suryawanshi S; Drisko J; Meehan A; Waldstreicher J;
J Urol; 2004 Mar; 171(3):1194-8. PubMed ID: 14767299
[TBL] [Abstract][Full Text] [Related]
32. Comparison of the efficacy and safety of finasteride in older versus younger men with benign prostatic hyperplasia.
Kaplan SA; Holtgrewe HL; Bruskewitz R; Saltzman B; Mobley D; Narayan P; Lund RH; Weiner S; Wells G; Cook TJ; Meehan A; Waldstreicher J;
Urology; 2001 Jun; 57(6):1073-7. PubMed ID: 11377309
[TBL] [Abstract][Full Text] [Related]
33. [Benign prostatic hyperplasia. Finasteride controls progression of BPH].
MMW Fortschr Med; 2000 Jun; 142(25):62-3. PubMed ID: 10920676
[No Abstract] [Full Text] [Related]
34. Long-term treatment with finasteride in men with symptomatic benign prostatic hyperplasia: 10-year follow-up.
Lam JS; Romas NA; Lowe FC
Urology; 2003 Feb; 61(2):354-8. PubMed ID: 12597947
[TBL] [Abstract][Full Text] [Related]
35. Treatment of experimentally induced benign prostatic hyperplasia with Tadalafil and castration in dogs.
Dearakhshandeh N; Mogheiseh A; Nazifi S; Ahrari Khafi MS; Abbaszadeh Hasiri M; Golchin-Rad K
Theriogenology; 2020 Jan; 142():236-245. PubMed ID: 31711694
[TBL] [Abstract][Full Text] [Related]
36. Effects of 5 alpha-reductase inhibition by finasteride on lipoproteins and body composition in males affected by benign prostatic hyperplasia (BPH).
Denti L; Pasolini G; Cortellini P; Sanfelici L; Benedetti R; Cecchetti A; Ferretti S; Banchini A; Ablondi F; Valenti G
J Endocrinol Invest; 1999; 22(10 Suppl):70-1. PubMed ID: 10727053
[No Abstract] [Full Text] [Related]
37. [Effect of dutasteride on reduction of plasma DHT following finasteride therapy in patients with benign prostatic hyperplasia].
Botto H; Lan O; Poulain JE; Comenducci A
Prog Urol; 2005 Dec; 15(6):1090-5. PubMed ID: 16429658
[TBL] [Abstract][Full Text] [Related]
38. Does long-term finasteride therapy affect the histologic features of benign prostatic tissue and prostate cancer on needle biopsy? PLESS Study Group. Proscar Long-Term Efficacy and Safety Study.
Yang XJ; Lecksell K; Short K; Gottesman J; Peterson L; Bannow J; Schellhammer PF; Fitch WP; Hodge GB; Parra R; Rouse S; Waldstreicher J; Epstein JI
Urology; 1999 Apr; 53(4):696-700. PubMed ID: 10197843
[TBL] [Abstract][Full Text] [Related]
39. The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. Veterans Affairs Cooperative Studies Benign Prostatic Hyperplasia Study Group.
Lepor H; Williford WO; Barry MJ; Brawer MK; Dixon CM; Gormley G; Haakenson C; Machi M; Narayan P; Padley RJ
N Engl J Med; 1996 Aug; 335(8):533-9. PubMed ID: 8684407
[TBL] [Abstract][Full Text] [Related]
40. Quantitative evaluation of glandular and stromal compartments in hyperplastic dog prostates: effect of 5-alpha reductase inhibitors.
Laroque PA; Prahalada S; Molon-Noblot S; Cohen SM; Soper K; Duprat P; Peter CP; van Zwieten MJ
Prostate; 1995 Sep; 27(3):121-8. PubMed ID: 7567690
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
